Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium
MWN-AI** Summary
Palisade Bio, Inc. (Nasdaq: PALI) has announced its participation in the Piper Sandler Virtual Novel Targets in Immunology Symposium, scheduled for February 12, 2026, from 1:30 PM to 1:55 PM ET. The event will feature JD Finley, the Company’s Chief Executive Officer, and Dr. Mitchell Jones, the President and Chief Medical Officer, engaging in a virtual fireside chat. This symposium will focus on emerging therapeutic targets and approaches in immunology, led by industry analysts and will include discussions with both public and private companies.
Palisade Bio, a clinical-stage biopharmaceutical company based in Carlsbad, California, specializes in developing next-generation, once-daily oral PDE4 inhibitor prodrugs. Their lead product, PALI-2108, is designed for targeted delivery and activation in the terminal ileum and colon by local bacterial bioactivation, which addresses challenges posed by systemic PDE4 inhibitors, such as poor tolerability and adverse side effects.
Recent positive results from a Phase 1b trial of PALI-2108 showed a 100% clinical response in the ulcerative colitis (UC) cohort, with no severe adverse events. The Company plans to advance to a Phase 2 clinical study focusing on the clinical remission, response, and pharmacodynamics of PALI-2108 over 12 weeks, alongside an extension phase to evaluate maintenance of remission.
Investors interested in the event can access a live webcast on Palisade's website, with a replay available post-event. As the company marks its progress toward addressing chronic inflammatory and fibrotic diseases, the outcomes of forthcoming studies will provide critical insight into the effectiveness and safety of PALI-2108, forming an integral part of Palisade Bio's growth strategy.
MWN-AI** Analysis
As Palisade Bio (Nasdaq: PALI) prepares to participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium on February 12, 2026, investors should closely monitor this event as it may significantly impact the company’s stock performance. The symposium will feature key insights from CEO JD Finley and CMO Dr. Mitchell Jones, allowing stakeholders to glean important updates on the company's lead product, PALI-2108, a once-daily oral PDE4 inhibitor prodrug.
PALI-2108’s unique pharmacological profile, designed for targeted delivery to the terminal ileum and colon, represents a potential breakthrough in treating inflammatory bowel diseases (IBD). Early results from the Phase 1b trial, which reported a 100% clinical response in ulcerative colitis (UC) patients, coupled with minimal adverse effects, highlight the promising safety and efficacy profile of PALI-2108. As Palisade moves toward a Phase 2 clinical study, objectives focusing on clinical remission and pharmacodynamic biomarkers will be critical to establishing the product’s market viability.
Investors should be aware of the inherent risks during this clinical stage, including potential delays in trial enrollment or outcomes not meeting expectations. Monitoring management commentary during the fireside chat could provide insights into these uncertainties and the company’s long-term strategic directions.
Given the promising developments around PALI-2108, potential investors might consider initiating or increasing their position in Palisade Bio. However, maintain caution regarding the speculative nature of clinical-stage investments. The upcoming symposium presents an opportunity to assess the robustness of the management’s vision and to evaluate the overall trajectory of the company's development pipeline. Watching for analyst commentary post-event could also be advantageous in determining market sentiment surrounding PALI-2108 and Palisade Bio’s future.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Virtual fireside chat scheduled for Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET
Access the webcast here
Carlsbad, CA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President and Chief Medical Officer, will participate in a virtual fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET.
The symposium will host analyst-led fireside chats and discussions with public and private companies exploring emerging targets and therapeutic approaches in immunology. In addition to the fireside chat, management will be available to participate in one-on-one in-person meetings with qualified members of the investor community who are registered to attend the conference.
A live webcast of the presentation will be accessible on the Events page in the Investors section of the Company’s website at palisadebio.com. A replay will be available following the live event and will be archived for a limited time.
About PALI-2108
PALI-2108 is a once-daily, oral prodrug designed for targeted delivery of PDE4 inhibition to the terminal ileum and colon through local bacterial bioactivation. The prodrug is pharmacologically inactive until it reaches the lower intestine, where bacterial enzymes convert it into the active PDE4 inhibitor at sites of inflammation and fibrosis. This targeted activation strategy prevents absorption in the upper gut, enables sustained local exposure with controlled systemic distribution, and is engineered to reduce peak plasma levels, thereby improving the overall therapeutic index and reducing tolerability limitations such as diarrhea, nausea and headache that have constrained systemic PDE4 inhibitors.
About Palisade Bio
Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”) is a clinical-stage biopharmaceutical company advancing a next generation oral PDE4 inhibitor prodrugs designed to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases. Through its differentiated prodrug platform and precision pharmacology strategy, Palisade Bio is committed to transforming proven PDE4 biology into better, safer oral therapies for patients living with chronic inflammatory and fibrotic diseases.
The Company’s lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colon, initiating targeted PDE4 inhibition at sites of disease while enabling systemic distribution of the active drug. In a recently reported Phase 1b trial, PALI-2108 achieved a 100% clinical response in the UC cohort, with no serious adverse events, favorable tolerability and pharmacokinetics consistent with localized activation in the lower intestine, low systemic exposure, and controlled release within the GI tract.
Palisade Bio is now advancing towards a Phase 2 clinical study in UC designed to evaluate clinical remission, response and pharmacodynamic biomarkers over 12 weeks, with an extension phase assessing maintenance of remission. In addition, the Company is completing early studies in FSCD to further characterize PALI-2108’s safety, pharmacology and potential therapeutic benefit across inflammatory bowel disease indications. For more information, please go to www.palisadebio.com.
Forward Looking Statements
Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to: statements regarding the timing and results of clinical trials, the potential mechanisms of action and therapeutic benefits of PALI-2108, and plans for regulatory submissions. These forward-looking statements are based on the Company’s current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company’s forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company’s clinical trials; the Company’s reliance on PALI-2108, and its early stage of clinical development; the risk that prior results, such as signals of safety, activity, dosing or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company’s product candidates in clinical trials focused on the same or different indications; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 24, 2025, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com
FAQ**
During the fireside chat on February 12, 2026, what specific advancements or insights about Palisade Bio Inc. PALI and its lead program PALI-2108 do you expect JD Finley and Dr. Mitchell Jones to share regarding its clinical development progress?
How will Palisade Bio Inc. PALI address potential investor concerns regarding the risks associated with the ongoing clinical trials for PALI-2108 during the upcoming fireside chat?
What key performance metrics or results from the Phase 1b trial of PALI-2108 do you anticipate being highlighted by Palisade Bio Inc. PALI during the discussion on February 12, 2026?
Can we expect Palisade Bio Inc. PALI to provide updates on the timeline and strategies for the Phase 2 clinical study of PALI-2108 in ulcerative colitis during the virtual fireside chat?
**MWN-AI FAQ is based on asking OpenAI questions about Palisade Bio Inc. (NASDAQ: PALI).
NASDAQ: PALI
PALI Trading
2.41% G/L:
$1.915 Last:
2,194,896 Volume:
$1.90 Open:
